Second Adcetris patient reported to develop fatal brain virus
Word has come down of a second patient who was receiving Seattle Genetics' flagship oncology product Adcetris (brentuximab vedotin) who has developed the often fatal brain virus progressive multifocal leukoencephalopathy (PML). The company has reported the case to the FDA, but has not released any information on the health or welfare of the patient.
The first patient who developed PML while receiving Adcetris did so during the clinical trial phase and is deceased, but this was hardly a well-kept secret. Rather, Adcetris' prescribing information includes this information.
Adcetris, long known as SGN-35, was approved by the FDA in the late summer of 2011 for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphoma.
Progressive multifocal leukoencephalopathy (PML) has a lengthy association with the development of targeted treatments, as it has been an issue among patients taking the monoclonal antibody Rituxan, and was enough of an issue to cause natalizumab (Tysabri) to be removed from the market temporarily.
Source: Xconomy
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
